tetano
Editor, Senior Moderator
Int J Infect Dis
. 2022 Jul 1;S1201-9712(22)00382-4.
doi: 10.1016/j.ijid.2022.06.044. Online ahead of print.
Changes in Interferon-Gamma Release Assay Readout after COVID-19 Vaccination: A Prospective Cohort Study
Nan-Yu Chen[SUP] 1 [/SUP], Zhuo-Hao Liu[SUP] 2 [/SUP], Shu-Wei Kao[SUP] 1 [/SUP], Huang-Shen Lin[SUP] 3 [/SUP], Ing-Kit Lee[SUP] 4 [/SUP], Jun-Yuan Zheng[SUP] 5 [/SUP], Ssu-Wei Wang[SUP] 1 [/SUP], Yu-Hsiang Hsiao[SUP] 1 [/SUP], Hui-Chin Lin[SUP] 6 [/SUP], Ting-Shu Wu[SUP] 7 [/SUP]
Affiliations
Abstract
Objectives: Interferon-gamma release assays (IGRAs) are widely used in public health practice to diagnose latent tuberculosis. During the coronavirus disease (COVID-19) pandemic and rollout of COVID-19 vaccination, it has remained unclear whether COVID-19 vaccines interfere with IGRA readouts.
Methods: We prospectively recruited healthcare workers during their annual occupational health examinations in 2021. Baseline IGRA readouts were compared with follow-up data after the participants had received two doses of COVID-19 vaccination.
Results: A total of 134 baseline IGRA-negative cases (92 with ChAdOx1 vaccine, 27 with mRNA-1273 vaccine, and 15 with heterologous vaccination) and seven baseline IGRA-positive cases were analysed. Among the baseline IGRA-negative cases, there were decreased interferon-γ concentrations over the Nil (p = 0.005) and increased Mitogen-Nil (p < 0.001) values post-vaccination. For TB2-Nil value, there was a similar trend (p = 0.057) of increase observed. Compared with the 0.35 IU/mL threshold, the baseline and follow-up readout differences were less than |±0.10| IU/mL over the TB1-Nil and TB2-Nil values in >90% baseline IGRA-negative cases. No significant readout difference was observed among baseline IGRA-positive cases.
Conclusions: COVID-19 vaccination did not change IGRA interpretation in most cases. Cases showing conversion/borderline IGRA readouts should be given special consideration.
Keywords: COVID-19; QuantiFERON; interferon-gamma release assay; latent tuberculosis; vaccine.
. 2022 Jul 1;S1201-9712(22)00382-4.
doi: 10.1016/j.ijid.2022.06.044. Online ahead of print.
Changes in Interferon-Gamma Release Assay Readout after COVID-19 Vaccination: A Prospective Cohort Study
Nan-Yu Chen[SUP] 1 [/SUP], Zhuo-Hao Liu[SUP] 2 [/SUP], Shu-Wei Kao[SUP] 1 [/SUP], Huang-Shen Lin[SUP] 3 [/SUP], Ing-Kit Lee[SUP] 4 [/SUP], Jun-Yuan Zheng[SUP] 5 [/SUP], Ssu-Wei Wang[SUP] 1 [/SUP], Yu-Hsiang Hsiao[SUP] 1 [/SUP], Hui-Chin Lin[SUP] 6 [/SUP], Ting-Shu Wu[SUP] 7 [/SUP]
Affiliations
- PMID: 35788418
- DOI: 10.1016/j.ijid.2022.06.044
Abstract
Objectives: Interferon-gamma release assays (IGRAs) are widely used in public health practice to diagnose latent tuberculosis. During the coronavirus disease (COVID-19) pandemic and rollout of COVID-19 vaccination, it has remained unclear whether COVID-19 vaccines interfere with IGRA readouts.
Methods: We prospectively recruited healthcare workers during their annual occupational health examinations in 2021. Baseline IGRA readouts were compared with follow-up data after the participants had received two doses of COVID-19 vaccination.
Results: A total of 134 baseline IGRA-negative cases (92 with ChAdOx1 vaccine, 27 with mRNA-1273 vaccine, and 15 with heterologous vaccination) and seven baseline IGRA-positive cases were analysed. Among the baseline IGRA-negative cases, there were decreased interferon-γ concentrations over the Nil (p = 0.005) and increased Mitogen-Nil (p < 0.001) values post-vaccination. For TB2-Nil value, there was a similar trend (p = 0.057) of increase observed. Compared with the 0.35 IU/mL threshold, the baseline and follow-up readout differences were less than |±0.10| IU/mL over the TB1-Nil and TB2-Nil values in >90% baseline IGRA-negative cases. No significant readout difference was observed among baseline IGRA-positive cases.
Conclusions: COVID-19 vaccination did not change IGRA interpretation in most cases. Cases showing conversion/borderline IGRA readouts should be given special consideration.
Keywords: COVID-19; QuantiFERON; interferon-gamma release assay; latent tuberculosis; vaccine.